8% Off
Ponatinix15 mg
Beacon Pharmaceuticals PLC
৳6040.72
Out Of Stock
Generic medicine
Ponatinib Hydrochloride: Brands, Price & Uses in Bangladesh
Ponatinib Hydrochloride is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) indicated for the treatment of adult patients with the following conditions: Established/FDA-approved uses…
About Ponatinib Hydrochloride
Indications of Ponatinib Hydrochloride
Ponatinib Hydrochloride is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) indicated for the treatment of adult patients with the following conditions:
Established/FDA-approved uses
- Chronic myeloid leukemia (CML), chronic phase that is resistant or intolerant to at least two prior tyrosine kinase inhibitors.
- Accelerated phase or blast phase CML for patients for whom no other tyrosine kinase inhibitor therapy is indicated.
- CML (any phase) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) harboring the T315I mutation, a mutation that confers resistance to most other TKIs.
- Ph+ ALL for whom no other kinase inhibitor therapy is indicated, as monotherapy.
Uses requiring combination therapy
- Newly diagnosed Ph+ ALL, in combination with chemotherapy, based on achievement of minimal residual disease (MRD)-negative complete remission.
Important limitation
Ponatinib Hydrochloride is not recommended for newly diagnosed chronic-phase CML because of its comparatively higher risk of serious vascular adverse events relative to other available TKIs. It is generally reserved by specialists for patients who are resistant to, or intolerant of, other TKIs, or who have T315I mutation-positive disease.
Dosage & Administration of Ponatinib Hydrochloride
Dosing of Ponatinib Hydrochloride is individualized by indication, response, and tolerability, and must be prescribed and monitored by a hematologist-oncologist. All doses are taken orally, once daily.
| Indication | Starting dose | Dose reduction on response |
|---|---|---|
| Chronic-phase CML | 45 mg once daily | Reduce to 15 mg once daily after achieving ≤1% BCR::ABL1(IS) |
| Accelerated- or blast-phase CML | 45 mg once daily | Dose reduction may be considered after major cytogenetic response |
| Ph+ ALL (monotherapy, T315I-positive or no other TKI indicated) | 45 mg once daily | Continue until loss of response or unacceptable toxicity |
| Newly diagnosed Ph+ ALL (with chemotherapy) | 30 mg once daily | Reduce to 15 mg once daily after MRD-negative complete remission |
Treatment is generally discontinued if there is no appropriate hematologic, cytogenetic, or molecular response within about 3 months, per specialist assessment. See Dosage for full detail on dose reductions for toxicity and Precautions and Warnings for monitoring requirements.
Side Effects of Ponatinib Hydrochloride
The most common adverse reactions (occurring in more than 20% of patients) associated with Ponatinib Hydrochloride as a single agent include:
- Rash and dry skin
- Arthralgia and other musculoskeletal pain
- Abdominal pain, constipation, nausea
- Fatigue and fever
- Headache
- Hypertension
- Elevated liver enzymes (hepatotoxicity)
- Fluid retention/edema
- Pancreatitis or asymptomatic lipase elevation
- Hemorrhage
- Anemia and other cytopenias (thrombocytopenia, neutropenia)
- Arterial occlusive events and cardiac arrhythmias
Serious adverse effects requiring urgent medical attention include arterial occlusive events (heart attack, stroke, limb ischemia), venous thromboembolism, heart failure, severe hepatotoxicity/liver failure, severe pancreatitis, serious bleeding, severe myelosuppression, gastrointestinal perforation, and reversible posterior leukoencephalopathy syndrome (RPLS). See Precautions and Warnings for the boxed-warning risks and required monitoring.
Contraindications of Ponatinib Hydrochloride
Ponatinib Hydrochloride is contraindicated in patients with known hypersensitivity to ponatinib or any component of the formulation. There are no other well-established absolute contraindications; all other risk factors (e.g., cardiovascular disease, prior thrombosis, hepatic disease) require careful specialist risk-benefit assessment rather than automatic exclusion from therapy, and are addressed under Precautions and Warnings.
Frequently Asked Questions about Ponatinib Hydrochloride
What is Ponatinib Hydrochloride used for?
Ponatinib Hydrochloride is used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients who are resistant or intolerant to other tyrosine kinase inhibitors or who have the T315I mutation. It is prescribed and monitored by a specialist hematologist-oncologist.
Why does Ponatinib Hydrochloride carry a boxed warning?
Ponatinib Hydrochloride carries boxed warnings for serious and sometimes fatal arterial occlusive events (heart attack, stroke, limb ischemia), venous thromboembolism, heart failure, and hepatotoxicity (including liver failure). Because of these risks, treatment requires close cardiovascular and liver monitoring throughout therapy.
Can Ponatinib Hydrochloride be used during pregnancy?
Ponatinib Hydrochloride can cause fetal harm and should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only after consulting a physician. Women of reproductive potential should use effective contraception during and for at least 3 weeks after treatment.
What monitoring is needed while taking Ponatinib Hydrochloride?
Patients on Ponatinib Hydrochloride require regular blood pressure checks, liver function tests, complete blood counts, serum lipase monitoring, and periodic eye examinations, along with ongoing cardiovascular risk assessment, all supervised by the treating specialist.
What should I do if I miss a dose of Ponatinib Hydrochloride?
If a dose of Ponatinib Hydrochloride is missed, take it as soon as remembered on the same day; if an entire day is missed, skip that dose and resume the normal schedule the next day. Do not take a double dose.
Is Ponatinib Hydrochloride safe for children?
The safety and efficacy of Ponatinib Hydrochloride in children have not been established, and it is not approved for pediatric use outside specialist-directed clinical settings.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.